Non-coding RNAs As Potential Biomarkers and Therapeutic Targets in Polycystic Kidney Disease

Overview

Journal Front Physiol

Date 2022 Oct 7

PMID 36203940

Authors

Qi Zheng

Glen Reid

Michael R Eccles

Cherie Stayner

Affiliations

Soon will be listed here.

Abstract

Polycystic kidney disease (PKD) is a significant cause of end-stage kidney failure and there are few effective drugs for treating this inherited condition. Numerous aberrantly expressed non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), may contribute to PKD pathogenesis by participating in multiple intracellular and intercellular functions through post-transcriptional regulation of protein-encoding genes. Insights into the mechanisms of miRNAs and other ncRNAs in the development of PKD may provide novel therapeutic strategies. In this review, we discuss the current knowledge about the roles of dysregulated miRNAs and other ncRNAs in PKD. These roles involve multiple aspects of cellular function including mitochondrial metabolism, proliferation, cell death, fibrosis and cell-to-cell communication. We also summarize the potential application of miRNAs as biomarkers or therapeutic targets in PKD, and briefly describe strategies to overcome the challenges of delivering RNA to the kidney, providing a better understanding of the fundamental advances in utilizing miRNAs and other non-coding RNAs to treat PKD.

Citing Articles

Gene therapy in polycystic kidney disease: A promising future.

Xue C, Lv J, Yang B, Mei S, Xu J, Li X J Transl Int Med. 2025; 12(6):543-552.

PMID: 39802450 PMC: 11720931. DOI: 10.1515/jtim-2024-0021.

Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases.

Bravo-Vazquez L, Paul S, Colin-Jurado M, Marquez-Gallardo L, Castanon-Cortes L, Banerjee A Genes (Basel). 2024; 15(1).

PMID: 38275604 PMC: 10815231. DOI: 10.3390/genes15010123.

Novel α-1,3-Glucosyltransferase Variants and Their Broad Clinical Polycystic Liver Disease Spectrum.

Boerrigter M, Te Morsche R, Venselaar H, Pastoors N, Geerts A, Hoorens A Genes (Basel). 2023; 14(8).

PMID: 37628703 PMC: 10454741. DOI: 10.3390/genes14081652.

Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease-The Promised Land?.

Pana C, Stanigut A, Cimpineanu B, Alexandru A, Salim C, Nicoara A Medicina (Kaunas). 2023; 59(5).

PMID: 37241147 PMC: 10224545. DOI: 10.3390/medicina59050915.

References

GARDNER Jr K, Burnside J, Elzinga L, Locksley R . Cytokines in fluids from polycystic kidneys. Kidney Int. 1991; 39(4):718-24. DOI: 10.1038/ki.1991.87. View

Patel V, Williams D, Hajarnis S, Hunter R, Pontoglio M, Somlo S . miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A. 2013; 110(26):10765-70. PMC: 3696812. DOI: 10.1073/pnas.1301693110. View

Dweep H, Sticht C, Kharkar A, Pandey P, Gretz N . Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model. PLoS One. 2013; 8(1):e53780. PMC: 3542345. DOI: 10.1371/journal.pone.0053780. View

Hirotsune S, Yoshida N, Chen A, Garrett L, Sugiyama F, Takahashi S . An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene. Nature. 2003; 423(6935):91-6. DOI: 10.1038/nature01535. View

Liu G, Kang X, Guo P, Shang Y, Du R, Wang X . miR-25-3p promotes proliferation and inhibits autophagy of renal cells in polycystic kidney mice by regulating ATG14-Beclin 1. Ren Fail. 2020; 42(1):333-342. PMC: 7241494. DOI: 10.1080/0886022X.2020.1745236. View

Yheskel M, Lakhia R, Cobo-Stark P, Flaten A, Patel V . Anti-microRNA screen uncovers miR-17 family within miR-17~92 cluster as the primary driver of kidney cyst growth. Sci Rep. 2019; 9(1):1920. PMC: 6374450. DOI: 10.1038/s41598-019-38566-y. View

Torres V, Harris P, Pirson Y . Autosomal dominant polycystic kidney disease. Lancet. 2007; 369(9569):1287-1301. DOI: 10.1016/S0140-6736(07)60601-1. View

Straarup E, Fisker N, Hedtjarn M, Lindholm M, Rosenbohm C, Aarup V . Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 2010; 38(20):7100-11. PMC: 2978335. DOI: 10.1093/nar/gkq457. View

Sun L, Hu C, Wang Z, Zhang X . MiR-182 inhibits kidney fibrosis by regulating transforming growth factor β1/Smad3 pathway in autosomal dominant polycystic kidney disease. IUBMB Life. 2020; 72(7):1340-1348. DOI: 10.1002/iub.2255. View

10.

Torres V, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q . Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol. 2010; 5(7):1312-29. PMC: 5619657. DOI: 10.2215/CJN.01360210. View

11.

Muller R, Messchendorp A, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O . An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney.... Nephrol Dial Transplant. 2022; 37(5):825-839. PMC: 9035348. DOI: 10.1093/ndt/gfab312. View

12.

Tsai Y, Teng I, Jiang S, Lee Y, Chiou Y, Cheng F . Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy. Adv Healthc Mater. 2019; 8(5):e1801358. DOI: 10.1002/adhm.201801358. View

13.

Hajarnis S, Patel V, Aboudehen K, Attanasio M, Cobo-Stark P, Pontoglio M . Transcription Factor Hepatocyte Nuclear Factor-1β (HNF-1β) Regulates MicroRNA-200 Expression through a Long Noncoding RNA. J Biol Chem. 2015; 290(41):24793-805. PMC: 4598991. DOI: 10.1074/jbc.M115.670646. View

14.

Norman J . Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta. 2011; 1812(10):1327-36. PMC: 3166379. DOI: 10.1016/j.bbadis.2011.06.012. View

15.

Choi S, Kim D, Ahn Y, Lee E, Park J . Suppression of by miR-132-3p Accelerates Cyst Formation by Up-Regulating ROS in Autosomal Dominant Polycystic Kidney Disease. Biomol Ther (Seoul). 2021; 29(3):311-320. PMC: 8094068. DOI: 10.4062/biomolther.2020.197. View

16.

Liu X, Haniff H, Childs-Disney J, Shuster A, Aikawa H, Adibekian A . Targeted Degradation of the Oncogenic MicroRNA 17-92 Cluster by Structure-Targeting Ligands. J Am Chem Soc. 2020; 142(15):6970-6982. PMC: 7357852. DOI: 10.1021/jacs.9b13159. View

17.

Streets A, Magayr T, Huang L, Vergoz L, Rossetti S, Simms R . Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. Am J Physiol Renal Physiol. 2017; 312(4):F577-F588. PMC: 5504395. DOI: 10.1152/ajprenal.00607.2016. View

18.

Kim D, Woo Y, Lee S, Oh S, Shin Y, Shin J . Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease. FASEB J. 2018; 33(2):2870-2884. DOI: 10.1096/fj.201800563RR. View

19.

Yang Y, Tang F, Wei F, Yang L, Kuang C, Zhang H . Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1 expression in ApoE knockout mice. Aging (Albany NY). 2019; 11(22):10016-10030. PMC: 6914395. DOI: 10.18632/aging.102388. View

20.

Ben-Dov I, Tan Y, Morozov P, Wilson P, Rennert H, Blumenfeld J . Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS One. 2014; 9(1):e86856. PMC: 3906110. DOI: 10.1371/journal.pone.0086856. View